Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Atai Beckley Inc.NASDAQ: ATAI

Operating Expenses · Q2 FY2026 · quarter ended Jun 2026

Operating expenses grows, but more slowly than its trailing trend

Q2 FY2026 operating expenses of $45.63M rose 77.1% year over year, behind the +82.4% change in trailing-twelve-month operating expenses. Sequentially, it rose 44.0% from the prior quarter. Over 3 fiscal years it compounded at -10.7% a year.

Context

  • Operating expenses amounted to 2515.0% of revenue in FY2025, down 30772.7 pp from a year earlier.
  • Operating expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +77.1% toward the trailing-twelve-month pace of +82.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$45.63M+44.0% QoQ
Last fiscal yearDec 2025
$102.84M+0.3% YoY
LTMJun 2026
$150.32M+82.4% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+77.1%——
1 year+0.3%——
3-year CAGR-10.7%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
102.84M USD
Year-over-year change
+0.3%
4-year CAGR
-7.5%

Operating Expenses vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +82.4% is the highest of 11, against a peer median of +17.1%.
  • Operating expenses amounts to 3360.6% of revenue for ATAI, versus a peer median of 1551.5%.
ATAI Competitors
Operating Expenses for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$436.26M USD+12.8%+42.4%200.9%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$251.79M USD+69.1%+76.0%2432.8%
IMTXImmatics N.V.LTM Mar 2026€250M EUR+22.1%+17.2%670.3%
SANASana Biotechnology, Inc.LTM Mar 2026$235.17M USD+10.6%-13.2%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$219.67M USD+63.0%+70.8%11537.4%
NKTRNektar TherapeuticsLTM Jun 2026$185.46M USD+13.6%-15.7%339.7%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$175.63M USD+53.3%-11.5%—
ATAIAtai Beckley Inc.LTM Jun 2026$150.32M USD+82.4%-10.7%3360.6%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$149.59M USD+2.2%+15.6%—
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$135.32M USD+20.5%+45.5%—
INBXInhibrx Biosciences, Inc.LTM Mar 2026$122.59M USD-58.9%+85.0%9429.8%
Peer median (excluding ATAI) —+17.1%+29.8%1551.5%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.38M233K314K308K4.09M
Cost of Revenue47K168K319K473K1.01M
Gross Profit20.33M65K(5K)(165K)3.08M
Gross Margin99.8%27.9%-1.6%-53.6%75.3%
Research & Development47.91M74.15M61.88M54.98M53.06M
Selling, General & Admin92.75M70.35M63.58M47.54M49.78M
Operating Expenses140.65M144.5M125.47M102.53M102.84M
Depreciation & Amortization47K168K319K473K1.01M
EBITDA(178.19M)(150.1M)(39.9M)(147.33M)(657.68M)
EBITDA Margin-874.5%-64419.3%-12708.3%-47835.4%-16084.0%
Operating Income(120.33M)(144.43M)(125.47M)(102.69M)(99.76M)
Operating Margin-590.5%-61987.1%-39958.9%-33341.2%-2439.7%
Interest Income205K548K1.85M778K1.48M
Interest Expense0923K2.66M3.12M1.16M
Other Income / Expenses(57.91M)(6.76M)82.59M(48.24M)(560.09M)
Income Before Tax(178.23M)(151.19M)(42.88M)(150.93M)(659.85M)
Pre-Tax Margin-874.7%-64887.6%-13655.7%-49003.2%-16137.2%
Income Tax Expense(3.99M)6.23M1.02M(881K)298K
Net Income(167.81M)(152.39M)(40.22M)(149.27M)(660.05M)
Net Margin-823.6%-65401.3%-12810.2%-48464.0%-16142.0%
EPS (Basic)(1.04)(0.98)(0.25)(0.93)(2.91)
EPS (Diluted)(1.04)(0.98)(0.25)(0.93)(2.91)
Weighted Avg Shares160.68M155.72M158.83M160.16M226.53M
Weighted Avg Shares (Diluted)160.68M155.72M158.83M160.16M226.53M

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.